OUTLOOK Minority Interest vs Selling And Marketing Expenses Analysis
| OTLK Stock | USD 2.01 0.31 18.24% |
OUTLOOK THERAPEUTICS financial indicator trend analysis is much more than just breaking down OUTLOOK THERAPEUTICS INC prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether OUTLOOK THERAPEUTICS INC is a good investment. Please check the relationship between OUTLOOK THERAPEUTICS Minority Interest and its Selling And Marketing Expenses accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OUTLOOK THERAPEUTICS INC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Minority Interest vs Selling And Marketing Expenses
Minority Interest vs Selling And Marketing Expenses Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of OUTLOOK THERAPEUTICS INC Minority Interest account and Selling And Marketing Expenses. At this time, the significance of the direction appears to have no relationship.
The correlation between OUTLOOK THERAPEUTICS's Minority Interest and Selling And Marketing Expenses is 0.08. Overlapping area represents the amount of variation of Minority Interest that can explain the historical movement of Selling And Marketing Expenses in the same time period over historical financial statements of OUTLOOK THERAPEUTICS INC, assuming nothing else is changed. The correlation between historical values of OUTLOOK THERAPEUTICS's Minority Interest and Selling And Marketing Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Minority Interest of OUTLOOK THERAPEUTICS INC are associated (or correlated) with its Selling And Marketing Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling And Marketing Expenses has no effect on the direction of Minority Interest i.e., OUTLOOK THERAPEUTICS's Minority Interest and Selling And Marketing Expenses go up and down completely randomly.
Correlation Coefficient | 0.08 |
| Relationship Direction | Positive |
| Relationship Strength | Insignificant |
Minority Interest
Minority Interest is the portion of a subsidiary corporation stock that is not owned by the parent corporation. The magnitude of the minority interest in the subsidiary company is generally less than 50% of outstanding shares, otherwise the corporation would generally cease to be a subsidiary of the parent. Minority Interest can also be called non-controlling interest.All shareholders of OUTLOOK THERAPEUTICS INC whose combined shares represent less than 50% of the total outstanding shares issued by OUTLOOK THERAPEUTICS have a minority interest in OUTLOOK THERAPEUTICS.Selling And Marketing Expenses
Most indicators from OUTLOOK THERAPEUTICS's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into OUTLOOK THERAPEUTICS INC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OUTLOOK THERAPEUTICS INC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. At this time, OUTLOOK THERAPEUTICS's Enterprise Value is quite stable compared to the past year.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 1.5M | 1.6M | 3.2T | 3.3T | Depreciation And Amortization | 204.7K | 44.2K | 39.8K | 37.8K |
OUTLOOK THERAPEUTICS fundamental ratios Correlations
Click cells to compare fundamentals
OUTLOOK THERAPEUTICS Account Relationship Matchups
High Positive Relationship
High Negative Relationship
OUTLOOK THERAPEUTICS fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 19.7M | 22.8M | 28.5M | 32.3M | 28.8T | 30.3T | |
| Short Long Term Debt Total | 8.8M | 11.9M | 11.0M | 35.6M | 297.8B | 312.7B | |
| Other Current Liab | 3.8M | 1.7M | 3.4M | 2.7M | 32.7T | 34.3T | |
| Total Current Liabilities | 15.9M | 6.8M | 19.7M | 46.7M | 42.6T | 44.7T | |
| Total Stockholder Equity | 2.8M | 4.6M | 8.7M | (14.4M) | (73.1T) | (69.4T) | |
| Other Liab | 4.2M | 70.8K | 522.9K | 57.1K | 51.4K | 48.9K | |
| Net Tangible Assets | (16.1M) | 2.8M | 4.6M | 8.7M | 10.0M | 10.5M | |
| Property Plant And Equipment Net | 494.2K | 275.1K | 70.4K | 26.2K | 274.6B | 288.4B | |
| Net Debt | (3.7M) | (2.6M) | (6.4M) | 12.2M | (14.6T) | (13.9T) | |
| Retained Earnings | (289.7M) | (342.9M) | (408.9M) | (467.9M) | (543.3T) | (516.1T) | |
| Accounts Payable | 2.4M | 2.2M | 3.5M | 6.6M | 8.0T | 8.4T | |
| Cash | 12.5M | 14.5M | 17.4M | 23.4M | 14.9T | 15.7T | |
| Non Current Assets Total | 1.8M | 1.3M | 1.0M | 1.3M | 1.4T | 1.5T | |
| Non Currrent Assets Other | 394.4K | 174.6K | 132.0K | 501.3K | 1.1T | 1.2T | |
| Other Assets | 449.0 | (451.0) | 132.0K | 399.0 | 359.1 | 341.15 | |
| Long Term Debt | 98.5K | 50.3K | 904.2K | 10.9M | 12.5M | 13.1M | |
| Cash And Short Term Investments | 12.5M | 14.5M | 17.4M | 23.4M | 14.9T | 15.7T | |
| Common Stock Total Equity | 286.1K | 1.3M | 1.8M | 2.3M | 2.0M | 1.9M | |
| Common Stock Shares Outstanding | 3.6M | 7.6M | 10.6M | 12.5M | 18.5B | 19.5B | |
| Liabilities And Stockholders Equity | 19.7M | 22.8M | 28.5M | 32.3M | 28.8T | 30.3T | |
| Non Current Liabilities Total | 1.0M | 11.5M | 61.4K | 6.2K | 59.3T | 62.3T | |
| Other Current Assets | 4.6M | 7.0M | 10.1M | 7.6M | 12.5T | 13.1T | |
| Other Stockholder Equity | 291.3M | 345.7M | (28.5T) | 450.9M | 470.0T | 493.5T | |
| Total Liab | 16.9M | 18.2M | 19.8M | 46.7M | 101.9T | 107.0T | |
| Property Plant And Equipment Gross | 494.2K | 1.2M | 1.1M | 26.2K | 23.6K | 22.4K | |
| Short Long Term Debt | 3.7M | 904.2K | 10.9M | 35.6M | 40.9M | 42.9M | |
| Total Current Assets | 17.9M | 21.5M | 27.5M | 31.0M | 27.4T | 28.8T | |
| Accumulated Other Comprehensive Income | (19.7T) | (22.8T) | 417.7M | (32.3T) | (29.1T) | (27.6T) | |
| Short Term Debt | 7.9M | 973.5K | 11.0M | 35.6M | 50.9B | 53.5B | |
| Common Stock | 1.3M | 1.8M | 2.3M | 2.6M | 239.1B | 251.0B | |
| Property Plant Equipment | 3.2M | 327.2K | 163.6K | 70.4K | 63.3K | 60.2K | |
| Long Term Debt Total | 3.6M | 3.4M | 904.2K | 10.9M | 12.5M | 6.4M | |
| Retained Earnings Total Equity | (254.5M) | (289.7M) | (342.9M) | (408.9M) | (368.0M) | (386.4M) | |
| Capital Surpluse | 238.1M | 291.3M | 345.7M | 415.4M | 477.7M | 278.9M | |
| Capital Lease Obligations | 4.2M | 112.3K | 43.0K | 4.3K | 3.8K | 3.6K | |
| Non Current Liabilities Other | 3.9M | 113.3K | 565.9K | 61.4K | 55.3K | 52.5K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OUTLOOK THERAPEUTICS INC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OUTLOOK THERAPEUTICS. If investors know OUTLOOK will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OUTLOOK THERAPEUTICS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.06) | Revenue Per Share 0.119 | Quarterly Revenue Growth 6.583 | Return On Assets (0.84) | Return On Equity (0.04) |
The market value of OUTLOOK THERAPEUTICS INC is measured differently than its book value, which is the value of OUTLOOK that is recorded on the company's balance sheet. Investors also form their own opinion of OUTLOOK THERAPEUTICS's value that differs from its market value or its book value, called intrinsic value, which is OUTLOOK THERAPEUTICS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OUTLOOK THERAPEUTICS's market value can be influenced by many factors that don't directly affect OUTLOOK THERAPEUTICS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OUTLOOK THERAPEUTICS's value and its price as these two are different measures arrived at by different means. Investors typically determine if OUTLOOK THERAPEUTICS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OUTLOOK THERAPEUTICS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.